Exicure (XCUR) Stock: Buy, Sell, or Hold?
$1.10
-0.01 (-0.90%)
âŧ
5d:
+23.58%
30d:
-9.09%
90d:
-12.0%
Open in Live Scanner
70/30 Portfolio Builder
Earnings: Nov 13, 2026
TODAY
Updated Nov 11, 12:00 AM ET
QUANTITATIVE VERDICT
WAIT
LOW Confidence (67%)
Quality Score
39/100
Position
SLIGHTLY HIGH
30-Day Fair Range
$0.97 â $1.12
Position: SLIGHTLY HIGH
Wall Street Target
$2.00
+80.2% upside
Options IV & Volume
HIGH Vol
HIGH volume confirmation
Support / Resistance
$0.78 / $1.19
Trend: Strong Downtrend
Executive Thesis & Bottom Line
Forward Earnings Fair Value & Price Prediction →
âšī¸ NEUTRAL: XCUR is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
Get Alerted When XCUR Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
In-depth Analysis How we analyze
Valuation Analysis: XCUR is currently trading at $1.10, which is considered slightly high relative to its 30-day fair value range of $0.97 to $1.12.
Technical Outlook: Technically, XCUR is in a strong downtrend. Immediate support is located at $0.78, while resistance sits at $1.19.
Market Sentiment: The stock scores a mixed 42/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $2.00 (+80.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, XCUR is in a strong downtrend. Immediate support is located at $0.78, while resistance sits at $1.19.
Market Sentiment: The stock scores a mixed 42/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $2.00 (+80.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$0.97 -
$1.12
Company Quality Score
39/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
66.8%
Trading Range & Key Levels
30-Day Trading Range
$0.97 -
$1.12
Current vs Trading Range
SLIGHTLY HIGH
Support Level
$0.78
Resistance Level
$1.19
Current Trend
Strong Downtrend
Technical data as of
Nov 12, 2026
Quantitative Signal Breakdown
- NEUTRAL: Mixed technical signals (42/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 80.2% below Wall St target ($2.00)
- WARNING: Composite score 39/100 in the bottom quintile â this cohort historically lags the market
Fundamental Context
Wall Street Target
$2.00
(+80.2%)
Revenue Growth (YoY)
928.0%
Share XCUR Analysis
Share this live XCUR analysis (with rich preview card) to Reddit, StockTwits, X, or embed the chart on your blog.
bloggers & journalists: you are free to use our charts with attribution.Reddit & Retail Trader Sentiment (XCUR)
Bullish
1 Retail Mentions
StockTwits Volume
1 msgs
24h retail stream
Last Tracked
Nov 11, 2026
Daily AI digest
AI Retail Discussion Summary:
Exicure, Inc. (XCUR) announced the sale of its GPC-100 program assets to GPCRT Inc. for approximately US$4.8 million. The sale includes the rights under Exicure's License and Collaboration Agreement, intellectual property, clinical and regulatory data, materials and equipment used in the GPC-100 program.
Key Retail Themes:
Asset sale
GPC-100 program
Aggregated from r/wallstreetbets, r/stocks & StockTwits streams.
View All Trending Reddit & WSB Stocks →
Last updated: November 12, 2026 3:07 PM ET
Data refreshes hourly during market hours. Next update: 4:07 PM
Data refreshes hourly during market hours. Next update: 4:07 PM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is XCUR showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CYTK
Cytokinetics Inc |
STRONG BUY
22 analysts |
$107 | 65 BUY |
|
INSM
Insmed Inc |
STRONG BUY
24 analysts |
$194 | 37 SELL |
|
MDGL
Madrigal PharmaceuticalsâĻ |
STRONG BUY
19 analysts |
$689 | 58 HOLD |
|
CRNX
Crinetics PharmaceuticalâĻ |
STRONG BUY
17 analysts |
$86 | 46 HOLD |
|
IMNM
Immunome Inc |
STRONG BUY
17 analysts |
$35 | 46 HOLD |
Explore More Analysis & Live Quant Tools
Part A: Deep-Dive XCUR Research Pages